At a glance
ClinicalIndex Comparison RecordN/AUnknown· 142 target
Drug / intervention
Hyperfractionated IMRT +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.
In Brief
A clinical study evaluating Hyperfractionated IMRT and Conventional Fraction IMRT for Nasopharyngeal Neoplasms and 3 related conditions. Targeting 142 participants across 1 site.
Detailed Summary
This study evaluates the hyperfractionated IMRT in the treatment of patients with locally recurrent nasopharyngeal carcinoma. Half of participants will receive hyperfractionated IMRT, while the other half will receive conventional fraction IMRT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Neoplasms, Mortality, Quality of Life, Complications
CountriesChina
Collaborators--
Timeline
N/AUnknownOverdue
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJun 2015
Primary CompletionDec 2022
Study CompletionMar 2023
TodayJul 2026
First PostedMay 28, 2015
Enrollment StartJun 1, 2015
Primary CompletionDec 1, 2022
Study CompletionMar 1, 2023
TodayJul 1, 2026
Enrollment to primary: 7.5 yearsPosted 11.1 years ago
Interventions
Hyperfractionated IMRTradiation
Conventional Fraction IMRTradiation